Abstract
Congenital junctional ectopic tachycardia (JET) is a rare tachyarrhythmia found in young infants and is often difficult to treat. JET is characterized by incessant tachycardia which causes ventricular dysfunction, heart failure and high mortality. Ivabradine is one of the newer antiarrhythmic drugs with special indications in decreasing heart rate in adults with chronic heart failure. It has shown promising role in congenital JET. However, there are no guidelines recommending ivabradine as a first-line agent for congenital JET. We report an infant with congenital JET who was successfully treated with ivabradine.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
